Randomized, Open-Label, 2-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 22 Jun 2017 Status changed from recruiting to completed.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.
- 06 Mar 2017 New trial record